The landscape of oncology has been fundamentally reshaped by the advent of adoptive cell therapies, particularly T cell receptor-engineered T cell (TCR-T) therapy. Unlike Chimeric Antigen Receptor (CAR) T cells, which areRead More…
The landscape of targeted therapeutics and diagnostics is experiencing a profound paradigm shift. For decades, monoclonal antibodies have dominated the field of targeted biologicals. However, the rise of oligonucleotides has brought aRead More…
In the rapidly evolving landscape of therapeutic protein development, the integration of Artificial Intelligence (AI) has shifted the paradigm from “discovery via screening” to “discovery via design.” However, even the most sophisticatedRead More…
In the landscape of modern drug discovery, the era of simply finding a molecule that “binds” to a target is over. The contemporary challenge lies in functional precision—dictating exactly how a therapeuticRead More…
De novo drug design has moved from a niche computational exercise to a central pillar of AI-driven drug discovery. With rising R&D costs, multi-year timelines, and high attrition rates, the ability toRead More…
As operators of Creative Biolabs’ AI Station, we’ve watched artificial intelligence move natural-product (NP) drug discovery from scattered experiments to data-driven pipelines. A recent perspective captures this shift with unusual clarity: AIRead More…
The landscape of cancer treatment is undergoing a radical transformation, driven by the emergence of messenger RNA (mRNA) vaccines. These versatile and scalable platforms are not just a new tool; they representRead More…
The design of therapeutic antibodies has long been a cornerstone of modern biopharmaceutical innovation. Yet traditional discovery pipelines—reliant on animal immunization, patient-derived antibodies, and wet-lab optimization—are inherently slow, costly, and difficult toRead More…
In the evolving landscape of biologics, monoclonal antibodies (mAbs) have emerged as one of the most powerful therapeutic modalities, offering high specificity, prolonged half-life, and unparalleled versatility in disease targeting. Yet, despiteRead More…
Artificial intelligence (AI) is rapidly transforming the landscape of therapeutic antibody discovery and engineering. As the biopharmaceutical industry continues to demand faster, more precise, and cost-effective development pipelines, AI-driven solutions have emergedRead More…